XANTUS-EL, Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A Noninterventional Study
Phase of Trial: Phase IV
Latest Information Update: 30 Aug 2017
Price : $35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism; Stroke; Thromboembolism
- Focus Adverse reactions
- Acronyms XANTUS-EL
- Sponsors Bayer
- 30 Aug 2017 Results of pooled analysis of three observational studies (XANTUS, XANAP and XANTUS-EL) presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
- 25 Jul 2016 Status changed from active, no longer recruiting to completed.
- 15 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jun 2016.